Zobrazeno 1 - 2
of 2
pro vyhledávání: '"T. V. R. Upendra"'
Autor:
Luz Delgado, Roopa Rai, Shailender Chauhan, Patricio Avila, Dhananjay I. Patel, Glenda Fuentealba, Camila Flores, Kevin P. Quinn, T. V. R. Upendra, Vijay Kumar Sharma, Sarvajit Chakravarty, Anjan Kumar Nayak, Emma McCullagh, Gonzalo Ureta, Ramona Almirez, Brahmam Pujala, Sebastian Bernales, Jennifer Alfaro, David T. Hung, Son Minh Pham, Diana Gaete, Sebastian Belmar, Felipe Pérez de Arce, Stacy Kanno, Claudia Acuña, Anup Barde
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 361:312-321
Although new targeted therapies, such as ibrutinib and idelalisib, have made a large impact on non-Hodgkin's lymphoma (NHL) patients, the disease is often fatal because patients are initially resistant to these targeted therapies, or because they eve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a88d9ba848c5c5372e62f468a36b17ce
https://doi.org/10.1124/jpet.116.238022
https://doi.org/10.1124/jpet.116.238022
Autor:
Jennifer, Alfaro, Felipe, Pérez de Arce, Sebastián, Belmar, Glenda, Fuentealba, Patricio, Avila, Gonzalo, Ureta, Camila, Flores, Claudia, Acuña, Luz, Delgado, Diana, Gaete, Brahmam, Pujala, Anup, Barde, Anjan K, Nayak, T V R, Upendra, Dhananjay, Patel, Shailender, Chauhan, Vijay K, Sharma, Stacy, Kanno, Ramona G, Almirez, David T, Hung, Sarvajit, Chakravarty, Roopa, Rai, Sebastián, Bernales, Kevin P, Quinn, Son M, Pham, Emma, McCullagh
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 361(2)
Although new targeted therapies, such as ibrutinib and idelalisib, have made a large impact on non-Hodgkin's lymphoma (NHL) patients, the disease is often fatal because patients are initially resistant to these targeted therapies, or because they eve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f7e8d9a06c49ef42e973fc8a84ac5ee2
https://pubmed.ncbi.nlm.nih.gov/28298527
https://pubmed.ncbi.nlm.nih.gov/28298527